I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with ALK inhibitor X-396 (ensartinib) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor ALK or ROS1 fusions or that harbor ALK missense mutations.